The generic name for Zepbound is tirzepatide [1]. Tirzepatide is also the active ingredient in Mounjaro, which is approved for type 2 diabetes [2].
What is Tirzepatide Used For?
Tirzepatide is approved for chronic weight management in adults with obesity or overweight who have at least one weight-related condition [1]. It is administered as an injection [1].
How Does Tirzepatide Work?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [3]. By targeting these receptors, it helps to regulate appetite and blood glucose levels, contributing to weight loss and improved glycemic control [3].
When Does Tirzepatide Patent Protection End?
Information regarding specific patent expiry dates for tirzepatide is available through patent databases. DrugPatentWatch.com tracks such information, providing details on when market exclusivity may end for branded drugs and their generic equivalents [4].
Who Manufactures Zepbound?
Zepbound is manufactured by Eli Lilly and Company [1].
What Are the Potential Side Effects of Tirzepatide?
Common side effects of tirzepatide include nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, indigestion, and fatigue [1]. Serious side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and thyroid tumors [1].
Are There Other Drugs Similar to Zepbound?
Other GLP-1 receptor agonists used for weight management include semaglutide (Wegovy) and liraglutide (Saxenda) [5]. Tirzepatide's dual action on GIP and GLP-1 receptors distinguishes it from these other medications [3].
What is the Difference Between Tirzepatide and Semaglutide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, while semaglutide is a GLP-1 receptor agonist only [3]. This difference in mechanism may lead to variations in efficacy and side effect profiles [3].
Can Tirzepatide Be Used for Diabetes?
Tirzepatide is also approved for type 2 diabetes under the brand name Mounjaro [2]. It helps improve blood sugar control in adults with type 2 diabetes [2].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218857s000lbl.pdf
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214459s007lbl.pdf
3. https://pubmed.ncbi.nlm.nih.gov/34774432/
4. https://drugpatentwatch.com/
5. https://www.niddk.nih.gov/health-information/weight-management/adult-weight-loss-medications